Mucopolysaccharidosis Type II - 80 Studies Found Enrolling by invitation : Long-Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Patients With Hunter Syndrome That Have Completed Study HGT-HIT-094 : Hunter Syndrome : 2015-04-01 : Drug: Idursulfase-IT Patients will receive idursulfase-IT treatment once every 28 days at a dose of 10 m Completed : Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase® : Hunter Syndrome : 2009-07-09 : Behavioral: Neurobehavioral testing Recruiting : Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II : Mucopolysaccharidosis II : 2017-01-13 : Biological: SB-913 Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor Active, not recruiting : Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment : : 2024-05-13 Active, not recruiting : Extension of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase (IT)in Conjunction With Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment : Hunter Syndrome : 2011-12-15 : Drug: Idursulfase-IT Idursulfase-IT administered once monthly at the dose used in study HGT-HIT-045 via Completed : Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase : Hunter Syndrome Mucopolysaccharidosis II< : 2008-02-28 : Biological: Idursulfase Solution for intravenous infusion, 0.5 mg/kg once-weekly Completed : Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy : Hunter Syndrome Mucopolysaccharidosis II< : 2008-01-22 : Biological: Idursulfase Solution for intravenous infusion, 0.5 mg/kg weekly Completed : Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II) : Mucopolysaccharidosis (MPS) Hunter Syndrome : 2013-03-12 Completed : Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome) : Mucopolysaccharidosis II : 1999-10-18 : Genetic: lymphocyte gene therapy Completed : Safety and Efficacy of Hunterase : Hunter Syndrome : 2012-07-16 : Biological: Hunterase once weekly, 0.5mg/kg IV infusion <<< Previous | Next >>>